VANCOUVER, British Columbia, Oct. 14, 2004 (PRIMEZONE) -- ProtoKinetix, Inc.'s (OTCBB:PKTX) Director of Medical Research, Dr. Jean-Marie Dupuis, announces today from Paris that the independent confirmation trials on the RECAF(tm) receptor site have produced results that strongly indicate the existence of this Alphafetaprotein binding site on most cancers.
As a result of the positive outcome of these trials being undertaken by the Georges Pompidou Hospital, ProtoKinetix's Scientific Advisory Board is proceeding with a research plan to develop a therapeutic, target specific, catalytic antibody. If successful, the Company believes that the catalytic antibody will be a highly effective pan cancer monoclonal antibody therapy.
About European Hospital Georges Pompidou
Located in Paris, France, Georges Pompidou is the most modern, full-service hospital in Europe. Completed only 4 years ago, it has become the flagship of European health care and is already one of the most advanced hospitals and research centers in the world.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors, Dr. John Todd, President Company Office: 1500-885 West Georgia Street Vancouver, BC V6C 3E8